Table 2.
Summary of the features assessed in neo-generated β-like cells ranked both chronologically and by frequency.
| Year | Insulin (%) | Pdx1 (%) | GSIS (%) | Nkx6.1/6.2 (%) | Glut2 (%) | NeuroD1 (%) | MafA (%) | Pax4 (%) | HG recovery (%) | Pax6 (%) | Glucokinase (%) | Foxa2 (%) | Isl1 (%) | PC1/3 (%) | Nkx2.2 (%) | Kir6.1/6.2 (%) | Sur1 (%) | PC2 (%) | Hlxb9 (%) | Iapp (%) | Urocortin3 (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011 | 100 | 100 | 75 | 50 | 75 | 63 | 38 | 13 | 50 | 63 | 38 | 25 | 25 | 13 | 13 | 13 | 25 | 0 | 13 | 0 | 0 |
| 2012 | 100 | 90 | 80 | 60 | 70 | 80 | 70 | 80 | 50 | 40 | 40 | 60 | 30 | 30 | 30 | 30 | 30 | 30 | 20 | 20 | 0 |
| 2013 | 100 | 100 | 88 | 50 | 75 | 63 | 75 | 63 | 63 | 63 | 13 | 13 | 38 | 38 | 13 | 13 | 0 | 13 | 13 | 0 | 0 |
| 2014 | 100 | 100 | 92 | 85 | 38 | 38 | 46 | 38 | 31 | 31 | 38 | 15 | 46 | 31 | 23 | 23 | 23 | 23 | 23 | 15 | 23 |
| 2015 | 100 | 83 | 92 | 42 | 42 | 33 | 50 | 50 | 42 | 17 | 42 | 25 | 17 | 33 | 33 | 25 | 25 | 17 | 0 | 25 | 0 |
| 2016 | 100 | 100 | 100 | 50 | 25 | 0 | 0 | 0 | 25 | 0 | 25 | 75 | 0 | 0 | 50 | 25 | 0 | 0 | 0 | 0 | 0 |
| 2017 | 100 | 75 | 100 | 75 | 25 | 50 | 25 | 50 | 75 | 25 | 0 | 0 | 25 | 25 | 0 | 25 | 25 | 0 | 0 | 0 | 25 |
| Total | 100 | 93 | 88 | 59 | 53 | 49 | 49 | 46 | 46 | 36 | 32 | 29 | 29 | 27 | 24 | 22 | 20 | 15 | 12 | 12 | 7 |
For each year, the percentage of publications having validated a particular feature is displayed. GSIS, Glucose Stimulated Insulin Secretion; HG recovery, HyperGlycemia recovery, see Methodology for a description of the validation criteria.
Color gradient reflecting the percentage of validated features.